Background. Intermittent preventive treatment of malaria during pregnancy (IPTp) reduces placental infection, maternal anemia, and low birth weight (LBW). However, the optimal dosing regimen in settings in which human immunodeficiency virus (HIV) is highly prevalent among pregnant women remains controversial.
in women infected with HIV, who have higher rates of malarial parasitemia, higher parasite densities and anemia rates, and more frequent placental infections and birth complications than do HIV-negative women [6 -8] .
In Zambia, both HIV and malaria are common, so their interaction has important public health implications. An estimated 3.4 million malaria cases, corresponding to 308 infections/1000 persons/year, occur in Zambia each year [9] . HIV seroprevalence among pregnant women ranges from 14.4% in rural locales to 26 .8% in urban areas [10] .
To address this problem, Zambia's Ministry of Health currently recommends intermittent preventive treatment of malaria during pregnancy (IPTp) using sulfadoxine-pyrimethamine (SP) [11] . However, the optimal dosing regimen in settings in which HIV is prevalent among pregnant women remains controversial. A subgroup analysis of HIV-positive pregnant women receiving IPTp in Kenya suggested that, for HIV-positive women, monthly SP was superior to 2 doses given once each in the latter 2 trimesters [12] . Given the post-hoc nature of this observation and its evident public health implications, we conducted a trial comparing the standard 2-dose SP IPTp regimen (S-IPTp) with intensive monthly SP IPTp (I-IPTp) among a cohort of HIVpositive pregnant Zambian women.
METHODS
Between January 2003 and October 2004, we conducted a randomized, double-blind, placebo-controlled study. Our primary outcomes were histological evidence of acute or chronic placental malaria, placental parasitemia, and maternal peripheral parasitemia at delivery. Secondary outcomes included birth weight (including LBW), prematurity, cord blood parasitemia, spontaneous miscarriage, stillbirth or neonatal death, neonatal jaundice, maternal anemia at delivery, third trimester maternal anemia, severe maternal adverse reactions to SP, and symptomatic maternal malarial infection during pregnancy.
Study setting. The study was conducted at 3 district health clinics (Masala, Lubuto, and Chipokota-Mayamba) in Ndola, an urban center in the Copperbelt Province of Zambia (population, 347,757) [13] . Malaria transmission in Ndola peaks during the rainy season (November-March). Anopheles gambiae and An. funestus are the main mosquito vectors.
Starting in December 2003, coincident with the start of our study, the Ndola District Health Management Team launched a campaign of indoor residual spraying (IRS) with pyrethroids and DDT within the Masala catchment area but not in the other 2 study clinic neighborhoods (Lubuto and Chipokota-Mayamba). During the study period, the National Malaria Control Center carried out annual rounds of in vivo efficacy testing of SP in children Ͻ5 years old at sentinel sites throughout Zambia. The adequate clinical response to SP was 92% in 2002 in Mpongwe, a district in the Copperbelt Province near Ndola [14] . In 2003 and 2004, testing was not performed in Mpongwe, but data from the nearest sentinel site, Mansa, revealed a rise in SP total treatment failure rates, from 14.5% in 2003 to 37% in 2004 [15] .
Sample size. Assuming a frequency of smear-positive placental malaria among HIV-positive women of 25% (as in Parise et al.'s study [12] ) and a 15% decline in placental malaria in the intervention group, with an ␣ of 5% and 80% power, 113 HIVinfected women were needed in each arm. Although Parise et al. enrolled only primigravidae and secundigravidae, we assumed similar rates of placental infection among women of all gravidity [16] . Assuming that 90% of those delivering in the health facility would have their placentas collected and 50% loss to follow-up [12] , our sample size target was 454 subjects.
Enrollment. At the start of the study, we helped expand voluntary counseling and testing (VCT) for HIV and nevirapine availability at each clinic. HIV-positive women were offered nevirapine for prevention of mother-to-child transmission of HIV. Potential participants were approached about the study only after completing VCT.
HIV-1-seropositive pregnant women of all gravidities who were between 16 and 28 weeks of gestation, were free of an acute illness requiring hospitalization, and were willing to deliver at a study clinic were eligible. Exclusion criteria included age Ͻ18 years, prior enrollment in this study, residence outside of or intent to move out of the clinics' catchment area, severe anemia (hemoglobin [Hb] level Ͻ6 g/dL), history of allergic reactions to sulfa drugs, prior major pregnancy complications (e.g., breech presentation, severe preeclampsia, and 2 cesarean sections), and major illnesses likely to influence pregnancy outcomes.
To minimize stigma, we initially offered enrollment to every tenth HIV-negative woman and later to every fifth HIV-negative woman. HIV-negative women were not randomized but received the standard 2-dose regimen.
Randomization. HIV-positive participants were assigned sequential identification numbers during enrollment corresponding to a sealed package of study drugs. Each pack contained 6 medication sheets, representing single monthly doses of medication or placebo. Each sheet consisted of 3 blister-packed tablets. Active tablets contained a total of 500 mg of sulfadoxine and 25 mg of pyrimethamine. Roche Pharmaceuticals prepared the study drugs and placebos in individual patient drug packs according to our randomization scheme.
HIV-positive mothers were randomized in blocks of 20 to 1 of 2 dosing schedules: 1 treatment course of SP per month (I-IPTp) or 1 course of SP per trimester (S-IPTp). Randomization codes were retained by the study statistician and stored in a locked cabinet at Boston University. The code was broken when data collection was complete and preliminary blinded analyses had been performed. To ensure that all mothers received at least the 2-dose SP regimen, the first and fourth monthly sheets of each pack always contained active SP, whereas sheets 2, 3, 5, and 6 contained SP (I-IPTp) or placebo (S-IPTp). Pregnant women who began the study at weeks 25 or 26 of gestation were administered their second SP treatment course at their second follow-up visit (i.e., 2 months after their initial study visit).
For quality control, we submitted 2 unused sets of drugs corresponding to the placebo and intervention arms to the World Health Organization's Centre for Quality Assurance of Medicines (Potchefstroom, South Africa). Analysis by high-pressure liquid chromatography confirmed that the intervening month (months 2, 3, 5, and 6) tablets contained either SP or placebo, whereas months 1 and 4 contained SP, as expected.
Study procedures. At baseline, we collected a mother's demographic information, measured fundal height, and obtained a drop of blood by fingerprick to measure Hb level and for preparation of thick and thin blood smears. Mothers were dewormed with mebendazole, received their first study treatment, and were provided with monthly folate and iron supplements. At monthly follow-up visits, participants completed a questionnaire, underwent an obstetrical examination, and had measurements of temperature and Hb. Study drug was administered monthly under direct observation until mothers reached 36 weeks of gestation. No doses were administered after 36 weeks because of the risk of neonatal kernicterus from sulfonamides. Pregnant women with documented fever or history of recent fever and a positive malaria smear were treated with oral quinine. Team members attempted to contact women if they were Ͼ2 days overdue for a scheduled follow-up visit.
At delivery, we measured maternal axillary temperature and maternal and infant Hb levels, obtained biopsy samples from the maternal and fetal sides of the placenta, and prepared thick blood smears of maternal peripheral blood, of maternal and fetal sides of the placenta, and of fetal cord blood. We measured infant weight and estimated the infant's gestational age using the Dubowitz criteria [17] . Mothers returned for follow-up visits at 1 and 6 weeks post partum for determination of the infant's vital status and screening for residual drug adverse effects.
Laboratory analyses. A 2-step HIV testing protocol using Determine HIV 1/2 (Abbott Laboratories) as the screening test and Capillus (Cambridge Biotech) as the confirmatory test was performed, with the Bionor assay (Skien) used for indeterminate or discordant results.
Hb levels were measured using a HemoCue machine (HemoCue AB). Thick smears were prepared with a single drop of peripheral or placental blood and air dried. Slides were fixed in methanol and stained in 10% Giemsa at the Tropical Diseases Research Centre (TDRC) and were read independently by 2 parasitologists. The parasite density per microliter was the number of parasites per 200 leukocytes times 40 or the number per 500 leukocytes times 16 if no parasites were seen after counting 200 cells [18] . Slides were declared to be negative if no parasites were seen after counting 500 leukocytes.
Two 1-cm-wide full-thickness wedge placental biopsy samples were taken by measuring 5 cm centrifugally from the cord.
Samples were fixed in 20% formalin and embedded in paraffin wax. Sections that were 3 m thick were cut using a Rotary microtome (Lipshaw Manufacturing), fixed to a glass slide, and dehydrated in sequential ethanol baths. The slides were then stained in 0.1% hematoxylin and 1% eosin stains for 5 and 1 min, respectively.
Each slide was read independently by 2 Zambian pathologists (L.M. and C.K.M.). Slides were interpreted according to the classification scheme shown in table 1. Because pathological evidence of malaria might not be uniformly distributed throughout a placental sample, we assigned the interpretation with highest malaria intensity as the final classification. Thus, if a slide from a given section was interpreted as CN by one pathologist and as C3 on another section or by the second pathologist, the final reading was classified as C3.
Definitions. Pregnant women who presented with fever or a recent history of fever plus any level of parasitemia were categorized as having symptomatic uncomplicated malaria. Maternal peripheral parasitemia was defined as asexual stage parasites in thick smears made from maternal venous blood; placental malaria as positive histological evidence of malaria (C1, C2, or C3); placental parasitemia as the presence of parasites in thick smears of maternal-side placental blood; anemia as Hb level Ͻ11 g/dL; severe anemia as Hb level Ͻ6 g/dL; LBW as birth weight Ͻ2500 g; prematurity as 37 weeks of gestation by the Dubowitz criteria; stillborn as dead delivery after 28 weeks of gestation; spontaneously aborted as delivery before 28 weeks; and neonatal death as death occurring between days 0 ansud 28 post partum.
Statistical analysis. Data were double-entered into CS-Pro (United States Census Bureau). We used SAS (version 8.2; SAS Institute) for all analyses. Mothers with twins were excluded from the analysis of birth outcomes. We compared the proportions of the main study outcomes by calculating relative risks (RRs) and 95% confidence intervals (CIs) and compared continuous variables using independent t tests. Concordance between the pathologists' readings was estimated with the statistic. Gestational age was estimated from the last menstrual period (LMP) using a pregnancy calculator. Dubowitz scores were translated into gestational age on the basis of the original regression equation Y ϭ gestational age in weeks ϭ 0.2642x ϩ 24.595, where x ϭ the Dubowitz score [17] . If the discrepancy between the LMP-and Dubowitz-derived gestational age was Ͼ14 days, the Dubowitz score was used.
Ethical considerations. The Institutional Review Board of the Boston University Medical Center and the TDRC Ethics Committee approved the study. A data safety monitoring board consisting of 2 experts in international child and maternal health research and a statistician conducted a blinded interim safety analysis contrasting rates of serious adverse events midway through study enrollment.
RESULTS

Study population.
Of 456 HIV-positive women enrolled, 224 were randomized to the intensive regimen and 232 women to the standard regimen (figure 1). Baseline demographic and clinical characteristics were comparable in the 2 groups (table 2). There were significantly more primigravidae in the S-IPTp group, al- Figure 1 . Study profile. I-IPTp, intensive monthly sulfadoxine-pyrimethamine intermittent preventive treatment during pregnancy; S-IPTp, standard 2-dose sulfadoxine-pyrimethamine intermittent preventive treatment during pregnancy. though the absolute difference between groups was small (8%). Notably, there were no differences in insecticide-treated bed net use, recent antimalarial treatment, or proportion with peripheral parasitemia at baseline. Most participants in both groups had anemia at baseline. Baseline parasitemia rates increased during the rainy season (figure 2).
Similar proportions of mothers were lost to follow-up before delivery in the 2 groups (16.1% for I-IPTp vs. 13.8% for S-IPTp) (figure 1). Placental samples were collected from 95% of the 200 mothers in the S-IPTp group and from 91% of the 188 mothers in the I-IPTp group. There were 3 mothers who delivered twins in each group. Women who completed the study were more likely to be single and to have a flush toilet and were less likely to rent a house.
Efficacy of study regimens. Women in the I-IPTp group received a median of 4 doses, with 1% receiving only 1 dose, 5% receiving 2 doses, 29% receiving 3 doses, 36% receiving 4 doses, and 29% receiving 5 or more doses. In contrast, 84% of the S-IPTp group received 2 courses of SP, and the remainder received only 1 treatment course. The mean time between the last SP treatment and delivery was 6.7 weeks (SD, 4.3 weeks) in the standard group and 3.4 weeks (SD, 2.5 weeks) in the intensive therapy group. There were no significant differences between the 2 groups in terms of their mean Hb levels or proportion with anemia NOTE. Hb, hemoglobin; I-IPTp, intensive monthly sulfadoxine-pyrimethamine intermittent preventive treatment during pregnancy; RPR, rapid plasma reagin; S-IPTp, standard 2-dose sulfadoxine-pyrimethamine intermittent preventive treatment during pregnancy. a P ϭ .044. b Based on height of fundus. c n ϭ 231 (data missing for 1 participant).
during monthly antenatal visits (data not shown). Symptomatic uncomplicated malaria occurred less frequently in the I-IPTp group; this difference was significant (P ϭ .048) (table 3) . Placental biopsy samples were available for 78% (355/456) of the participants. At delivery, the proportion of women was similar in the 2 groups for placental malaria, any evidence of placental malaria by histology (C1ϩC2ϩC3), or placental parasitemia (table 3) . Substantially more women delivering around the rainy season had histological evidence of placental malaria (figure 3). Similar seasonal trends were noted for placental parasitemia (data not shown). There were also no differences for maternal anemia at delivery, birth weight, or proportion with LBW.
Stratification of the study participants by gravidity revealed that primigravidae and secundigravidae had a lower proportion of maternal parasitemia, placental malaria, and placental parasitemia in the I-IPTp than the S-IPTp group (table 4) ; however, none of these differences was statistically significant. There were no differences for any of these outcomes between the multigravidae in the 2 groups. Similarly, for secondary outcomes, there were lower rates of symptomatic malaria, maternal anemia, cord blood parasitemia, and LBW in the combined primigravidae and secundigravidae group in the I-IPTp treatment arm relative to the S-IPTp arm (table  5) , but these findings were also not statistically significant. With the exception of symptomatic malaria episodes, which were nonsignificantly lower in the I-IPTp group, there were no differences between multigravidae in the 2 study arms.
When stratifying outcomes by the number of SP doses received rather than by randomization group, single-dose SP IPTp Figure 2 . Proportion of women with baseline parasitemia, by enrollment date Table 3 . Delivery outcomes and anemia by treatment group. At 6 weeks, all-cause mortality was higher among the I-IPTp infants, but this difference was not significant (9/189 live deliveries for I-IPTp vs. 3/198 for S-IPTp; RR, 3.1 [95% CI, 0.86 -11.4]). All but 1 of the deaths occurred during the neonatal period. Of the 9 deaths in the I-IPTp group, 6 occurred in the delivery room, including 4 from birth asphyxia and 2 from severe prematurity; the other 3 deaths were from sepsis. All 3 deaths in the S-IPT group were from birth aspyhxia. Slightly more S-IPT infant deaths were stillbirths, but this difference was not significant (2/191 total deliveries vs. 5/203; RR, 0.43 [95% CI, 0.1-2.2]).
DISCUSSION
We found no evidence that intensive monthly dosing was superior to standard dosing of SP IPTp in HIV-seropositive women in terms of placental malaria, maternal anemia, or birth outcomes. Although rates of 2 primary outcomes (placental parasitemia and maternal peripheral parasitemia) and 2 secondary outcomes (symptomatic malaria episodes and cord blood parasitemia) were lower in the I-IPTp group, none of these differences were statistically significant, and the absolute reduction for each parameter was relatively small. However, since the 95% CIs are relatively wide for most outcomes (with the exception of placental malaria histopathology), we cannot be sure that these do not represent true differences.
A significant strength of this study was its double-blind, placebo-controlled design, considered the gold standard, which avoided theoretical biases associated with the open-label designs of prior IPTp studies [12, 20] . Additionally, we used the more sensitive primary outcome measure of placental histology [21] , rather than placental impression smears. Although we were unable to prove that I-IPTp was superior to S-IPTp, the findings are nevertheless highly relevant to the debate over the IPTp optimal policy. Compared with previous studies by Parise et al. [12] and Filler et al. [20] , the intensity of malaria transmission in our trial was lower, due perhaps to the periurban study sites, drier-than-usual rainy seasons, concurrent expansion of insecticide-treated bed net and IRS use in the Ndola region, and different study population characteristics. In Kenya, with high malaria transmission, Parise et al. [12] found that I-IPTp was more beneficial than S-IPTp-but only in the HIV-positive group. In Malawi, in a rural location with intense malaria transmission, I-IPTp was superior for HIV-positive and HIV-negative women alike [20] . In our study, with less intense malaria transmission, there was no difference between the regimens. This difference might be due to a lack of power secondary to lower rates of primary outcomes, with the notable exception of placental malaria based on histopathology, or to study design differences, such as enrollment of pregnant women of all gravidities in our study versus only primigravidae and secundigravidae in the Kenya and Malawi studies [12, 20] . We chose to evaluate IPTp in HIV-positive women of all gravidities given evidence that HIV-positive primigravidae had a risk of malaria similar to that of multigravid women [8, 16] and because use of broader eligibility criteria would make the results more generalizable.
Restricting our analysis to women in their first or second pregnancy revealed that rates of placental and peripheral parasitemia were lower in the I-IPTp group. Although the magnitude of this difference was similar to the Kenyan and Malawian studies, the absolute difference in placental parasitemia in our study was small and not statistically significant, perhaps because of lowerthan-expected malaria transmission. In contrast, placental malaria occurred slightly less frequently and past placental infection more often in the monthly dosing group among primigravidae and secundigravidae. There were few differences in these outcome measures among the multigravidae. Because of different malaria transmission dynamics and the need for a policy that addresses the needs of all pregnant women and not just those in their first or second pregnancy, our findings highlight the challenges in formulating a single, simple IPT policy that can be widely applied in sub-Saharan Africa.
Concerns have been raised about the continuing efficacy of SP IPT in areas of sub-Saharan Africa with high levels of SP treatment failures [22] . As described above, in vivo efficacy studies conducted at sentinel sites near our study site revealed a high efficacy of SP in young children [14] , with gradually rising treatment failure rates toward the study's end [15] . Although in vivo efficacy testing has not been done in pregnant women in Zambia, the high efficacy of SP in 2002 and 2003 in sentinel districts near the study site makes it unlikely that SP resistance was an issue. Moreover, adults are likely to have underlying partial immunity and therefore respond better than children in a setting of rising SP resistance. Regardless, SP was highly efficacious in eliminating peripheral parasitemia and reducing the risk of placental infection in both study regimens.
Of the 456 women enrolled, only 1 had a serious adverse reaction attributed to SP. This unfortunate woman developed fatal Stevens-Johnson syndrome ϳ3 weeks after her first SP treatment. Prolonged delays from the time of treatment to the development of a severe reaction are unusual but have been reported [23] [24] [25] , including fatal reactions in patients with AIDS receiving sulfonamides to prevent opportunistic infections [26, 27] . A recent review estimated a risk of severe adverse reactions to intermittent SP (monthly or less often) of 0%-6.3% [28] . Passive surveillance for severe adverse events associated with SP and trimethoprim-sulfamethoxazole in Malawi found that lifethreatening reactions (including Stevens-Johnson syndrome) occurred infrequently [29] . Rates were highest in HIV-positive adults (4.9/100,000 SP exposures). Fatal adverse reactions to SP were estimated to be 0.11 deaths/100,000 SP exposures. Although this is reassuring, the fatal reaction associated with SP in the present study highlights the importance of careful monitoring for serious reactions when SP is used for IPTp.
In conclusion, in contrast to prior studies of I-IPTp performed in sites with more intense malaria transmission [12, 19] , we found no convincing evidence that I-IPTp was superior to S-IPTp in an area of relatively mild malaria transmission. However, as described in the accompanying article [19] , single-dose SP IPTp is inferior to 2 doses for the prevention of maternal anemia, LBW, and prematurity. In addition, inadvertent underdosing is a potential vulnerability of standard-dose SP IPTp. From the efficacy standpoint, even though our study did not show a clear advantage of a monthly dosing schedule, factors related to effectiveness, such as the greater simplicity of monthly dosing at a programmatic level, argue in favor of a more intensive schedule.
